Macrophage and Microglial Activation in Glioma-Associated Inflammation
Macrophage and Microglial Activation in Glioma-Associated Inflammation
批准号:
7087265
负责人:
NALIN GUPTA
金额:
$16.14万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-19 至 2011-02-28
中文摘要
描述(由申请人提供):本项目的目标是提供申请人,纳林古普塔,与必要的专业知识,发展一个独立的研究生涯在加州旧金山弗朗西斯科的建设,他以前的经验和培训。这将通过Israel F博士监督的指导研究项目来实现。Charo,以及免疫学和转基因小鼠模型使用方面的额外培训。Gupta博士是一名儿科神经外科医生,对神经肿瘤学有临床和研究兴趣。他的项目“胶质瘤相关炎症中的巨噬细胞和小胶质细胞激活”解决了脑肿瘤生物学的一个未充分研究的方面:炎症细胞和肿瘤细胞之间的相互作用。该项目的假设是,巨噬细胞和小胶质细胞通过特异性趋化因子单核细胞趋化蛋白-1(MCP-1)的过度表达被招募到高级别胶质瘤中,并且该过程促进肿瘤生长。检验该假设的具体目的是:1)确定肿瘤相关巨噬细胞的来源,2)测量CCR 2细胞因子受体缺失对发生少突胶质细胞瘤的小鼠中胶质瘤生长的影响,3)确定肿瘤和宿主来源的MCP-1对胶质瘤生长的贡献。MCP-1在高级别胶质瘤中的普遍存在、与浸润性巨噬细胞的相关性以及支持该细胞因子在血管生成和肿瘤细胞迁移中的作用的数据表明了MCP-1的重要性。巨噬细胞和小胶质细胞对胶质瘤生长的影响将在转基因小鼠中使用遗传方法直接检查。在杂合ink 4a/arf背景下表达v-erbB癌基因的小鼠发生高级别肿瘤,且发生率可预测。这些肿瘤概括了人类高级别肿瘤的许多特征。对于特定目标1,动物将接受具有荧光标记细胞的骨髓移植,以便可以精确地识别骨髓来源的细胞。细胞因子活性对胶质瘤生长的影响将在Aim 2中通过将表达v-erbB的小鼠与缺乏MCP-1的细胞受体CCR 2的小鼠杂交来测量。将使用免疫组织化学和流式细胞术测量巨噬细胞和小胶质细胞。最终的目标将使用颅内植入转化的星形胶质细胞来研究肿瘤或宿主来源的MCP-1对肿瘤生长的影响。如果达到预期的结果,我们下一步将评估MCP-1/CCR 2信号通路的抑制剂作为潜在的抗肿瘤药物。公共卫生相关性:炎症伴随恶性脑肿瘤导致患者并发症,并可能促进肿瘤生长。确定炎症在脑肿瘤中的作用将为开发针对这一过程的药物提供理论基础。这类药物的另一个可能的好处是,与放射等治疗相关的正常组织损伤也可以减少。
英文摘要
DESCRIPTION (provided by applicant): The goal of this project is to provide the applicant, Nalin Gupta, with the necessary expertise to develop an independent research career at the University of California San Francisco by building on his previous experience and training. This will be accomplished through a mentored research project supervised by Dr. Israel F. Charo, and additional training in immunology and use of transgenic mouse models. Dr. Gupta is a pediatric neurosurgeon with a clinical and research interest in neuro-oncology. His project, 'Macrophage and microglial activation in glioma-associated inflammation' addresses an understudied aspect of brain tumor biology: The interactions between inflammatory cells and tumor cells. The hypothesis of this project is that macrophages and microglia are recruited to high-grade gliomas by over-expression of a specific chemokine, monocyte chemoattractant protein-1 (MCP-1), and that this process facilitates tumor growth. The Specific Aims that will test this hypothesis are: 1) determine the origin of tumor-associated macrophages, 2) measure the effect of loss of the CCR2 cytokine receptor on glioma growth in mice developing oligodendrogliomas, and 3) determine the contribution of tumor and host-derived MCP-1 on glioma growth. The importance of MCP-1 is suggested by its ubiquity in high-grade gliomas, its correlation with infiltrating macrophages, and data supporting a role for this cytokine in angiogenesis and tumor cell migration. The effect of macrophages and microglia on glioma growth will be directly examined using a genetic approach in transgenic mice. Mice expressing the v-erbB oncogene in a heterozygous ink4a/arf background develop high-grade tumors with a predictable incidence. These tumors recapitulate many of the features of human high-grade tumors. For Specific Aim 1, animals will receive bone marrow transplants with fluorescently labeled cells so that bone- marrow derived cells can be identified precisely. The effect of cytokine activity upon glioma growth will be measured in Aim 2 by crossing v-erbB expressing mice with mice that lack CCR2, the cellular receptor for MCP-1. Macrophage and microglia will be measured using immunohistochemistry and flow cytometry. The final Aim will use intracranial implantation of transformed astrocytes to study the effect of either tumor- or host-derived MCP-1 on tumor growth. If the expected results are achieved, we would next evaluate inhibitors of the MCP-1/CCR2 signaling pathway as potential anti-tumor agents. Public Health Relevance: Inflammation accompanying malignant brain tumors results in complications for patients, and may promote the growth of tumors. Identifying the role of inflammation in brain tumors would provide a rationale to develop drugs to target this process. Another possible benefit of such drugs is that normal tissue injury associated with treatments such as radiation may also be reduced.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects
-
批准号:10425330
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2020
-
负责人:NALIN GUPTA
-
依托单位:
Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects
-
批准号:10180919
-
项目类别:
-
资助金额:$37.41万
-
财政年份:2020
-
负责人:NALIN GUPTA
-
依托单位:
Myeloid cells and radiation-induced memory deficits in rodent glioma model: sex and age effects
-
批准号:10668445
-
项目类别:
-
资助金额:$36.69万
-
财政年份:2020
-
负责人:NALIN GUPTA
-
依托单位:
Therapeutic Irradiation and Brain Functions
-
批准号:10053714
-
项目类别:
-
资助金额:$35.16万
-
财政年份:2016
-
负责人:NALIN GUPTA
-
依托单位:
Macrophage and Microglial Activation in Glioma-Associated Inflammation
-
批准号:7389647
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2006
-
负责人:NALIN GUPTA
-
依托单位:
Macrophage and Microglial Activation in Glioma-Associated Inflammation
-
批准号:7225185
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2006
-
负责人:NALIN GUPTA
-
依托单位:
Macrophage and Microglial Activation in Glioma-Associated Inflammation
-
批准号:7582246
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2006
-
负责人:NALIN GUPTA
-
依托单位:
Macrophage and Microglial Activation in Glioma-Associated Inflammation
-
批准号:7776858
-
项目类别:
-
资助金额:$16.14万
-
财政年份:2006
-
负责人:NALIN GUPTA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
胶质瘤中miR-93的转录调控及其促细胞周期进展的新机制
-
批准号:81101915
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2011
-
负责人:张安玲
-
依托单位:
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
-
批准号:81101916
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:周旋
-
依托单位:
胶质瘤中miR-23b介导ICAT负调控β-catenin/TCF4信号通路的新机制
-
批准号:81001128
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2010
-
负责人:韩磊
-
依托单位:
基因修饰的人脐带间充质干细胞治疗胶质瘤的实验研究
-
批准号:81001009
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2010
-
负责人:范存刚
-
依托单位:
人脑胶质瘤Aurora A基因作用及其分子机制的研究
-
批准号:81072082
-
项目类别:面上项目
-
资助金额:33.0万元
-
批准年份:2010
-
负责人:夏之柏
-
依托单位:
胶质瘤中AKT/β-catenin信号转导通路转录调控miR-21的新机制
-
批准号:30971136
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:康春生
-
依托单位:
生物信息学筛选的miRNA对SEPT7的调控与胶质瘤恶性表型的关系研究
-
批准号:30872985
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2008
-
负责人:贾志凡
-
依托单位:
双向磷酸化调节P38MAPK信号通路在榄香烯抗脑胶质瘤增殖中的作用
-
批准号:30740027
-
项目类别:专项基金项目
-
资助金额:10.0万元
-
批准年份:2007
-
负责人:徐英辉
-
依托单位:
Thalidomide增强temozolomide对恶性胶质瘤治疗作用潜在机理的研究
-
批准号:30772228
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2007
-
负责人:杨学军
-
依托单位: